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Abstract. the status of the three retinoic acid receptors 
(rars) α, β and γ in human colorectal cancer (crc) has not 
as yet been examined. rars are in part responsible for the 
actions of the retinoids (vitamin a and its derivatives), which 
are essential for human health and survival due to their exten-
sive involvement in numerous cellular processes, in particular 
in epithelial morphology. the present study examined the 
expression of the three rars in crc using immunohisto-
chemical analysis of paraffin-embedded tissue sections. 
rar expression in tumor (t) and adjacent non-tumor (nt) 
specimens from stage i (n=6), stage ii (n=34), stage iii (n=26) 
and stage iV (n=14) crc patients was compared with that in 
normal mucous membranes (n=10) from control individuals. 
The findings were correlated with tumor grade, treatment 
response (progression during treatment, remission, chemore-
sistance) and survival as clinicopathological parameters. 
rarα and γ expression was decreased with crc stage in the 
t tissues (p=0.016 and p=0.052, respectively), suggesting that 
they may be used as predictive markers. rarβ expression in 
the nt tissues was associated with a more favorable prognosis 
(p=0.04). these results provide important information on the 
tumor microenvironment (the area adjacent to tumor cells).
Introduction
With its first description in 1925, Wolbach and Howe impli-
cated vitamin a and its derivatives (retinoids) in epithelial 
development and tumorigenesis (1). the activity of vitamin a, 
apart from that involved in vision, is mediated by retinoids. 
many years later, de luca further implicated the retinoids in 
differentiation and embryogenesis (2) by showing their effects 
on limb development, epithelial integrity and tumorigenesis. 
Since they are involved in numerous life processes (embryo-
genesis, cell growth, cell differentiation and cell death), 
retinoids are essential for life. One of their most important 
actions is their antitumor activity, whereby they inhibit tumor 
growth and promote apoptosis (3,4). this has led to their 
therapeutic application against cancer, for example in the 
treatment of acute promyelocytic leukemia (5,6).
retinoids cross the cell membrane through hydrophobic 
interactions and/or endocytosis in order to bind to their 
specific receptors: the retinoic acid receptors (RARs) (7) and 
rexinoid receptors (rxrs) (8-10). When retinoids are present 
in cells, they bind the rar/rxr heterodimer, which acts as 
a transcription factor. the retinoid-receptor complex binds to 
the retinoic acid response element sequence, located near the 
promoter of target genes, to induce or inhibit transcription (3).
the rar family comprises three members: α, β and γ. 
rarβ expression is frequently reduced in tumor cells, prob-
ably due to the hypermethylation of its promoter (11,12), and 
in association with tumor progression in different organs or 
with pathologies in head and neck tissues (13), basal skin 
cells (14), breast (15), lung (16), esophagus (17), prostate (18), 
thyroid (19), larynx (20), endometrium (12) and oral tissues 
(21). all of these studies have concluded that rarβ should 
be considered a tumor suppressor (22). however, studies on 
rarα and γ expression have reported conflicting results, 
depending on the pathology and the technique used.
to the best of our knowledge, the expression of the rars 
has not been reported in patients with colorectal cancer (crc). 
in France, crc is the second most common cancer in men 
and the third most common in women (23). this pathology 
is classified as the second leading cause of cancer-related 
death in industrialized countries (national cancer institute 
data), and the 5-year survival rate is very low. crc develop-
ment is characterized by four tumor stages, defined by the 
international pathology tumor node metastasis (ptnm) clas-
sification system (24), which is used as the diagnostic system 
upon which patient treatment is based. however, few proteins 
predictive of response have been identified. 
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rars are implicated in homeostasis and, in particular, in 
epithelial morphology, which led us to hypothesize that the 
expression of these receptors is implicated in crc develop-
ment. Since few predictive proteins are available for crc, the 
aim of this study was to examine the cellular distribution of 
the three rars by immunohistochemical analysis of normal 
and pathological human colon tissues from different tumor 
stages. their expression was compared to the cell prolifera-
tion rate, which is known to be associated with tumor growth, 
and was detected by immunostaining for ki-67. the results 
revealed the importance of rar signaling in the progression 
of crc. correlations with tumor grade, therapeutic response 
and survival were established.
Materials and methods
Patients and tissue samples. all cases of histologically 
confirmed CRC were included, regardless of whether the 
patients had received chemotherapy. based on the helsinki 
protocol, the exclusion criteria included juvenile patients, 
pregnant or breast-feeding women, rectal or colonic lesions 
that were not histologically confirmed to be CRCs, patients in 
whom follow-up was impossible and insufficient or unexploit-
able tissue due to inadequate preservation. 
Archived formalin-fixed paraffin-embedded blocks of 
colon tissues were obtained from the pathology department 
of the limoges teaching hospital. the specimens were 
from consecutive patients who underwent elective resection 
for crc between January 2006 and december 2007. Eighty 
patients (37 women and 43 men) with a mean age of 71 years 
(range 41-93) were included prospectively. The first follow-up 
evaluation was made on October 31, 2008, with a median 
follow-up time of 24 months (range 11-32). the second follow-
up evaluation was made on december 15, 2010, with a median 
follow-up time of 46 months (range 25-66). the tumors were 
graded according to the pTNM international classification 
(24). Forty patients had local disease (stage i, t1/2-n0, n=6; 
stage ii, t3/4-n0, n=34), 26 had regional lymph-node involve-
ment (stage iii, any t-n1/2) and 14 had advanced disease 
(stage iV, any t, any n, presence of metastasis). histological 
slides of the primary tumor were reviewed to identify the 
normal-appearing areas adjacent to the tumor sites and the 
tumor areas, excluding the central tumor zone, which was 
usually necrotic. the tissue blocks were sectioned (4-µm 
thick) and stained with h&E saffran (hES) for pathological 
diagnosis, tnm grading and immunostaining.
histologically normal colon tissues from 10 patients who 
had been treated for benign pathologies, such as idiopathic 
chronic constipation (n=7) or diverticulosis (n=3), constituted 
the control group and were used to determine the constitutional 
expression. 
Clinical and pathological parameters. clinical, paraclinical 
(biological and imaging) and histological parameters were 
collected by michelle nouaille and technicians at the 
pathology department, limoges teaching hospital, at 
the time of patient admission. the patients all underwent 
a uniform postoperative follow-up by the same team: they 
were examined within 1 month of resection, then every 
3-4 months for the first year, every 6 months for the next 
3 years and then at gradually increasing intervals. a clinical 
examination and quantification of serum carcinoembryonic 
antigen (cEa) were performed at each visit. computed 
tomographic (ct) scans were performed every 6-12 months. 
a full colonoscopy was performed 1 year after surgery, 
then once every 3-5 years. positron emission tomographic 
(pEt) scans were selectively performed when abnormalities 
or axial imaging raised the possibility of recurrence. local 
recurrence was defined as the first clinical, radiological and/
or pathological evidence of a tumor of the same histological 
type within the colon. Distant recurrence was defined as clin-
ical, radiological and/or pathological evidence of systemic 
disease at sites including, but not limited to, the liver, lungs, 
peritoneum and para-aortic region. recurrence-free survival 
and disease-specific survival were analyzed. ‘Evolution’ was 
defined as disease progression without adjuvant therapy, 
‘chemoresistance’ as disease progression during or after 
adjuvant therapy, and ‘remission’ as the absence of clinical 
signs of disease progression.
Antibodies. the antibodies used were rabbit polyclonal anti-
bodies raised against a peptide mapping to the c-terminus of 
human rarα (sc-551; Santa cruz biotechnology, le-perray-
en-Yvelines, France), human rarβ (sc-552) or human rarγ 
(sc-550). the commercially available antibody for ki-67 
(m7240; dakocytomation Sa, trappes, France), which recog-
nizes a 395-kda nuclear protein expressed during cell-cycle 
phases (G1, S, G2 and m) (25) was used. For the isotypic 
controls, we used immunoglobulin G (igG) (rabbit, i8140 and 
mouse, i8765; Sigma, St. Quentin Fallavier, France).
Control of antibody specificity. total proteins from the Widr 
cell line (american type culture collection) were extracted 
using a lysis buffer following the manufacturer's recom-
mendations (cell Signaling technology, Ozyme, St. Quentin 
Yvelines, France) in order to perform Western blotting. the 
results showed that rar proteins stained at the expected 
molecular weights, without non-specific binding, as deter-
mined with isotypic controls for the three anti-rar antibodies 
(data not shown). 
Immunohistochemistry. ki-67, rarα and rarγ were 
immuno-histochemically detected in paraffin-embedded 
tissues using the benchmark technology (Ventana medical 
Systems, illkirch, France). the pathway rarα and rarγ 
staining module was used according to the ki-67 protocol 
according to the manufacturer's instructions. the processing 
of the bar-code-labeled slides was fully automated and 
included the following steps: baking the slides, solvent-free 
deparaffinization and antigen retrieval in CC1 cell-condi-
tioning buffer (30 min at 95˚C). The samples were incubated 
with the primary antibody previously diluted in diluent solu-
tion (1:50 for ki-67, 1:100 for rarα and 1:150 for rarγ) 
for 32 min at 37˚C. Horseradish peroxidase (26)-coupled 
secondary antibody was added (8 min at 37˚C), thenthe 
proteins were detected with the chromogenic substrate diamin-
obenzidine (DAB) (8 min at 37˚C). The tissue sections were 
also counterstained with hematoxylin (12 min at 37˚C) and a 
bluing reagent (4 min at 37˚C) to increase the contrast. The 
slides were mounted with a non-aqueous mounting medium.
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For rarβ immunohistochemistry, paraffin sections were 
deparaffinized in toluene and alcohol, and rehydrated with 
phosphate-buffered saline (pbS). before staining, the sections 
were subjected to steam heat antigen retrieval in citrate buffer 
(200 µm citric acid, 9.8 mm sodium citrate, ph 7.0) for 
5 min. this step was repeated four times in a microwave oven 
(750 W). after washing in pbS, the slides were incubated 
for 10 min with 5% h2O2 in methanol to inhibit endogenous 
peroxidases. Non-specific sites were blocked with PBS-3% 
bovine serum albumin (bSa) for 30 min. the sections were 
then incubated with the primary antibody (1:500) in pbS-3% 
bSa for 1 h at room temperature. after washing, the epitopes 
were labeled with the anti-rabbit hrp Envision™ plus system 
and visualized with liquid dab (dako Sa). the sections were 
couterstained and examined with a leica microscope, and the 
images were captured with a Zeiss camera.
To test the specificity of the signals, negative control 
experiments were performed either by omitting the primary 
antibody, by substituting the primary antibody with non-
immune serum, or by omitting both the primary and secondary 
antibodies. no staining was observed in any of the negative 
controls (data not shown).
Quantification of immunostaining. photomicrographs of each 
slide were captured with a Zeiss microscope with a magnifica-
tion of x200. the most homogeneously stained tumor (t) and 
non-tumor (NT) areas on each slide were selected for quantifi-
cation. immunoreactivity was scored by a staining index based 
on the percentage of positive cells, by a semi-quantitative 
estimate, as follows: (-; 0), tissue with negative staining; (+; 1), 
tissue with staining in 25-49% of cells; (++; 2), tissue with 
staining in 50-74% of cells; (+++; 3), tissue with staining in 
≥75% of cells. ‘Overexpression’ was defined as a staining index 
of ≥75%. The results were expressed as the mean of three inde-
pendent quantifications made by different individuals.
Statistical analysis. the overall variations in the staining 
percentages for the rars and ki-67 and their relationships to 
tumor grade were evaluated by analysis of variance (anOVa) 
using SYStat 12.0 (SpSS, 2007). tukey's post hoc test was 
used to assess the significance of the differences between 
the stages, and P-values <0.05 were considered significant. 
correlations between the parameters were visualized by 
cluster analysis using Spearman's ρ as the measure of simi-
larity, using paSt 1.83 (27). Survival curves were constructed 
using the free-access software of the dartmouth-hitchcock 
norris cotton cancer center (http://biostat.hitchcock.org/
bSr/analytics/comparetwoSurvivaldistributions.asp).
Results
Baseline characteristics and overall survival. the overall 2-year 
survival rate was 70%, probably due to the age of the patients 
and the high proportion of advanced-stage cases. at the time of 
analysis, patient survival was 100% for stage i, 75% for stage 
ii, 65% for stage iii and 47% for stage iV. nine patients (8 with 
stage ii and 1 with stage iii) died of causes not related to crc 
(cardiac or neurological etiologies). adjuvant chemotherapy was 
administered for stages iii and iV. twenty patients received no 
adjuvant therapy (16 stage iii and 4 stage iV) due to postoperative 
death (n=3), age >85 years (n=14) and/or patient refusal (n=3). 
cancer progression occurred in 11/20 patients and cancer 
recurrence in 9/11 patients during adjuvant chemotherapy.
two years later, at the second evaluation, 77 patients had 
continued with the follow-up (3 had been lost). at this time, 
the overall 4-year survival rate was 49%; patient survival was 
100% for stage i, 48% for stage ii, 54% for stage iii and 23% 
for stage iV. apart from 5 stage ii patients who died due to 
unrelated causes, 10 patients (5 in stage ii, 1 in stage iii and 4 
in stage iV) succumbed to crc during the interval between 
the first and the second evaluations. 
Control of RAR expression in normal prostate. the use of 
antibodies against rars for immunohistochemistry of chemi-
cally fixed tissues was previously tested in prostate tissue (18). 
When different antibody dilutions (1:50 to 1:500) were tested, 
the results obtained in normal prostate tissue were reproduc-
ible, with localization patterns similar to those described by 
richter et al (18). as shown in Fig. 1 (arrows); for rarα, 
homogeneous staining in the cytoplasm with little nuclear 
staining was noted; for rarβ, the presence of staining in 
the basal nuclei was noted; for rarγ, homogeneous staining 
in the epithelial cytoplasm with little nuclear staining was 
observed. Since these results confirmed the specificity of the 
anti-rar antibodies, they were used on the crc tissues.
Ki-67 and RAR expression in different stages of CRC. the 
constitutional expression of the proteins was first evaluated 
Figure 1. immunohistochemical localization of rarα, β and γ in normal 
human prostate. Immunohistochemical staining was carried out on paraffin-
embedded sections (4-µm thick), using primary antibodies as follows: (a) 
anti-rarα (1:100 dilution), (b) anti-rarβ (1:100 dilution) and (c) anti-
rarγ (1:150 dilution). the Envision system was used as the secondary 
antibody. Original magnification, x200. 
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by immunohistochemistry in the normal control group, then 
examined in the adjacent nt tissue of each patient, for use as 
an internal control. The Ki-67 and RAR staining profiles in 
the nt tissues were identical to those observed in the control 
group. Finally, the expression of the rars was examined 
in the t and nt areas in the specimens from patients with 
different stages of crc.
random ki-67 staining was detected in the nuclei of all 
the cells, located both inside and outside the T fields, with 
some differences in the percentages of labeled cells among 
patients (data not shown). however, anOVa between the 
groups of different stages revealed no statistically significant 
differences (p>0.05).
rarα staining was uniformly detected in the cytoplasm 
of the epithelial cells in the nt and t tissues (Fig. 2). Of the 
80 patients analyzed, all expressed this receptor in the nt 
Figure 2. immunohistochemical localization of rarα in the tumor areas of samples from patients with different stages of crc. (a) Stage i, (b) stage ii, 
(C) stage III and (D) stage IV. Immunohistochemical staining was carried out on paraffin-embedded sections (4-µm thick) using a primary antibody against 
rarα (1:100) and the Envision system as the secondary antibody. Original magnification, x200. 
Figure 3. anOVa analysis of rarα expression in the tumor areas in dif-
ferent crc stages.
Figure 4. immunohistochemical localization of rarγ in the tumor areas of samples from patients with different stages of crc. (a) Stage i, (b) stage ii, 
(C) stage III and (D) stage IV. Immunohistochemical staining was carried out on paraffin-embedded sections (4-µm thick) using a primary antibody against 
rarα (1:150) and the Envision system as the secondary antibody. Original magnification, x200. 
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tissues (50-75% of cells), as did in the control group (data not 
shown). in the t tissues, only 6 (7.5%) (stage ii, n=1; stage iii, 
n=3 and stage iV, n=2) showed no expression, 11 (13.75%) 
showed weak expression, 20 (25%) showed moderate expres-
sion and most (n=43; 53.75%) showed strong rarα expression. 
At the inital evaluation, a statistically significant difference 
between stages was detected with anOVa (p=0.016) (Fig. 3). 
indeed, rarα expression in the t tissues was directly corre-
lated with tumor stage, as it was predominantly expressed in 
the early rather than the late stages of crc, when its expres-
sion decreased. reinforcing this result, this tendency was 
maintained at the second evaluation (p=0.0018) 
rarβ staining was restricted to the mucous membrane and 
was uniform in the cytoplasm of epithelial cells in the nt and 
t tissues. in the nt tissues, rarβ was expressed as a mean of 
71%, comparable to that observed in the normal control group 
(72.5%). in the t tissues, 15 patients (18.75%) (stage ii, n=7; 
stage iii, n=4; and stage iV, n=4) showed no expression, 4 (5%) 
showed weak expression, 6 (7.5%) showed moderate expres-
sion and most (55; 68.75%) showed strong rarβ expression. 
No statistically significant differences were observed between 
the crc stages as analyzed by anOVa (p>0.4).
rarγ staining was very similar to that observed for rarβ, 
as it was predominant in the cytoplasm of epithelial cells in 
both the nt and t tissues (Fig. 4). as with the other rars, 
the majority of patients expressed rarγ in the nt tissues 
(50-75% of cells), similar to the normal control group (data not 
shown). in the t tissues, only 1 (1.25%) (stage ii) showed no 
expression, 10 (12.5%) showed weak expression, 19 (23.75%) 
showed moderate expression and most (50; 62.5%) showed 
strong rarγ expression. rarγ expression tended to differ at 
each crc stage when assessed by anOVa (p=0.052) (Fig. 5). 
however, this value was probably attributable to the small 
number of patients in stage i (only 6 patients).
Correlation with patient outcome. rarα expression in 
the t tissues was positively correlated with crc stage 
[correlation coefficient (r)=0.0011] and remission (r=0.027). 
however, it was negatively correlated with disease evolution 
(r=0.012), chemoresistance (r=0.024) and death (r=0.0047). 
rarβ expression may be considered a marker of crc devel-
opment, as it decreased in conjuction with disease progression 
(confirmed by ANOVA at the two evaluations). Moreover, 
strong rarβ expression in the t tissues was associated with a 
more favorable survival probability (P=0.0072 at the first and 
p=0.1 at the second evaluation) (Fig. 6a and b). 
rarβ expression in the nt tissues may serve as a marker 
of a more favorable prognosis, as its expression was positively 
Figure 5. anOVa of rarγ expression in tumor areas of samples from 
patients with different stages of crc.
Figure 6. kaplan-meier estimation of survival probability of crc patients 
based on rarα expression in the tumor tissues. (a) Evaluation carried out 
at the first follow-up. Group 0, patients in which 0-25% of cells expressed 
rarα; group 1, patients in which 75-50% of cells expressed rarα. 
Estimated relative risk (rr) =0.327; standard error (SE) =0.136; p =0.0072. 
(b) Evaluation carried out at the second follow-up. Group 0, patients in 
which 0-25% of cells expressed rarα; group 1, patients in which 75-50% of 
cells expressed rarα. rr=0.558; SE=0.199; p=0.1.
  A
  B
Figure 7. kaplan-meier estimation of survival probability of crc patients 
based on rarβ expression in nt tissue. Group 0, patients in which 0-50% 
of cells expressed rarβ; group 1, patients in which 75% of cells expressed 
rarβ. the estimated relative risk is 0.355; the standard error is 0.179 and 
the p-value is 0.04.
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associated with remission (r=0.021) and negatively associated 
with disease evolution (r=0.022), chemoresistance (r=0.016) 
and death (r=0.033). although rarβ was also expressed in the 
nt tissues of the patients as the internal control group, its high 
expression was linked to a longer survival (p=0.04) (Fig. 7).
rarγ expression in the nt tissues was negatively 
associated with disease evolution (r=0.033). moreover, its 
expression in the t tissues was negatively associated with 
chemoresistance (r=0.014). based on these results, rarγ 
may be used as an indicator of a more favorable prognosis for 
CRC, although no significant association with survival prob-
ability was found (p>0.05).
Discussion
in the present study, the expression of the proliferation marker 
ki-67 and the three rars in different stages of crc, including 
the rare analysis of stage i (which is rarely operated on), was 
analyzed by immunohistochemistry in both the t and nt areas 
(the latter representing the tumor environment) of each patient. 
ki-67 immunoreactivity was present in the nt and 
t tissues of all of the patients analyzed, but no correlation 
with tumor grade or other parameters was established. Strong 
Ki-67 reactivity was found in the T tissues, which confirmed 
the high proliferative activity of crc, but the proliferation 
rate was not an indicator of disease progression, as observed 
for prostate cancer (28).
rarβ expression is commonly lost in various tumor 
types (12-20). in this study, rarβ expression in the t tissues 
was not an indicator of tumor progression. different rarβ 
isoforms, with varying biological functions, have been identi-
fied. Two known RARβ promoters and alternative splicing 
give rise to three major isoforms in humans (β1, β2 and β4). 
rarβ2 is the most abundant, and the term rarβ used in 
the literature frequently refers to this isoform. the loss of 
rarβ2 expression during cancer development is associated 
with tumorigenesis and retinoid resistance. the induction of 
its expression suppresses carcinogenesis. rarβ4 expression 
is also increased in various types of cancer, but induction of 
its expression increases the growth of tumor cells that do not 
express rarβ2 (29). in the present study, expression of rarβ 
was examined without distinguishing its different isoforms, 
which explains our results. Evaluating the specific expression 
of the various rarβ isoforms in different crc stages and in 
pre-cancerous stages is of interest. rarβ expression in the 
NT tissues was the most significant finding of the study, as it 
was correlated with remission. therefore, as a positive marker, 
rarβ may be an indicator of patient response to treatment 
and a prognostic marker of a beneficial clinical outcome.
rarα expression in the t tissues was lower than that in 
the nt tissues and decreased from the early to late crc stages 
(first follow-up, P=0.016; second follow-up, P=0.0018), as has 
been shown in head and neck tumors (13), carcinogenesis of 
the endometrium (12) and breast tumors (30). its expression 
was also positively associated with remission, which reinforces 
the hypothesis that rarα is a  marker of disease progression.
Finally, rarγ expression in the t tissues decreased 
progressively with tumor stage (p=0.052), which suggests that 
rarγ may serve as an indicator of crc tumor progression, as 
previously found in the carcinogenesis of the endometrium (12) 
and oral lesions (21). its expression in the t tissues was also 
negatively correlated with chemoresistance. therefore, weak 
rarγ expression or its loss in t tissues may be an indicator 
of a poor clinical outcome. in parallel, its expression was 
negatively correlated with disease progression in the nt 
tissues. collectively, these results suggest that rarγ may be 
as a suitable indicator of treatment response for crc.
altered rar expression is associated with the tumorigenic 
transformation of cells. retinoids are potentially important 
due to their multi-target actions, and promising results have 
been obtained in different in vitro studies demonstrating the 
inhibition of cell growth, increased cell differentiation and the 
induction of apoptosis (3). although in vitro growth inhibition 
of human crc cells by retinoids or their analogues has been 
documented (31-33), prompting initial enthusiasm, the findings 
concerning their therapeutic efficacy in vivo remain controver-
sial. Conflicting results have emerged, and retinoid resistance 
has been reported (34). the adverse effects of retinoids are also 
considerable; therefore, they must be used with caution. Further 
studies are warranted to clarify the mechanisms of retinoids 
and to improve their clinical usefulness, in particular in crc.
in this patient cohort comprising 80 patients living in the 
limousin region of France, ki-67 and rar expression was 
evaluated in tissues from patients with different stages of crc 
by immunohistochemical analysis. the relationships found 
provide information complementary to the ptnm international 
classification. The mechanisms implied by the changes in RAR 
expression are not currently well defined. Further investigations 
are required to better understand the roles of retinoids in crc 
carcinogenesis, in particular the corroboration of these results 
by a study on rxr expression. it may be useful to examine 
rar expression in pre-cancerous patient tissues in order to 
improve patient care and the treatment of crc, the second most 
common cause of death by cancer in industrialized countries.
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